Catalyst Wire Dossier Catalyst Wire Dossier

ND0612 Levodopa/Carbidopa Subcutaneous Solution

Levodopa/Carbidopa subcutaneous formulation · NeuroDerm Ltd.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ND0612 Levodopa/Carbidopa Subcutaneous Solution, covering 2024-05-01 to 2024-05-01. Get the full timeline:

Most recent: Clinical Trial Update: A Safety, Tolerability, and Plasma Concentration Study of Levodopa/Carbidopa Subcutaneous Solution (ND0612) in Parkinson's Disease (PD) Patients [Phase 1]

See pricing